IQuum Gets FDA Emergency Use OK for H1N1 Molecular Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IQuum, a privately held molecular diagnostics firm, has gained Emergency Use Authorization from the US Food and Drug Administration for its Liat Influenza A/2009 H1N1 Assay.

The nucleic acid test can be performed from sample to result in 26 minutes. According to the firm, the Liat assay can detect and differentiate 2009 H1N1 influenza viral RNA from nasopharyngeal swab samples and has shown 100 percent agreement with an EUA comparator assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.